Eloxx Pharmaceuticals

Eloxx Pharmaceuticals | 1,924 followers on LinkedIn. Clinical-stage biopharma company developing novel RNA-modulating drug candidates to treat rare and ultra rare diseases. | Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases.